ERBB2 and breast carcinoma: Among the 14 evaluable breast cancer patients who underwent a research biopsy, 9 had hormone receptor-positive disease, 1 had HER2-amplified disease, 1 had HER2 status change from positive to negative, and 2 patients had triple negative breast cancer.